Platelet-to-Albumin Ratio: A Novel IgA Nephropathy Prognosis Predictor.
IgA nephropathy
cohort study
end-stage renal desease
platelet-to-albumin ratio
prognosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
12
2021
accepted:
20
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
epublish
Résumé
Chronic inflammation is related to the development of IgA nephropathy (IgAN). Emerging studies have reported that platelet-related parameters including platelet (PLT), platelet-to-albumin ratio (PAR), and platelet-to-lymphocyte ratio (PLR) are proved to be novel prognostic indicators for several inflammatory diseases. Whether platelet-related parameters could serve as predictors for IgAN remains unknown. A total of 966 IgAN patients were enrolled in this retrospective study and were divided into several groups based on the optimal cut-off value of the platelet-related parameters. End-stage renal disease was used as the renal endpoint. A 1:2 propensity score (PS) match was then carried out to eliminate significant differences at baseline. The area under the receiver operating characteristic curve (AUROC), Kaplan-Meier (K-M) curve, and Cox proportional hazards analyses were performed to evaluate their predictive effect. Without considering the effect of covariates, the K-M curve showed that PLT, PLR, and PAR were strongly correlated with the renal outcomes of IgAN. However, the AUROC revealed that the PAR and PLR had better predictive power than the PLT. Multivariate Cox regression adjusting for demographic data, pathological findings, treatment, and laboratory results indicated that compared with PLR, albumin and PLT, PAR seemed to be a better marker of adverse renal outcome, implying that PAR was the only platelet-related parameter that could be used as an independent risk factor. Notably, high PAR patients seemed to have more severe clinical manifestations and pathological lesions. However, after eliminating the influence of different baselines on outcome variables, the PAR could still predict the poor prognosis of IgAN. To more accurately evaluate the predictive power of the PAR, we analyzed the predictive effect of the PAR on patients with different clinicopathological characteristics through subgroup analysis. It was indicated that the PAR might better predict the prognosis and outcome of patients whose disease was already very severe. PAR might be used as an independent risk factor for IgAN progression.
Sections du résumé
Background
Chronic inflammation is related to the development of IgA nephropathy (IgAN). Emerging studies have reported that platelet-related parameters including platelet (PLT), platelet-to-albumin ratio (PAR), and platelet-to-lymphocyte ratio (PLR) are proved to be novel prognostic indicators for several inflammatory diseases. Whether platelet-related parameters could serve as predictors for IgAN remains unknown.
Methods
A total of 966 IgAN patients were enrolled in this retrospective study and were divided into several groups based on the optimal cut-off value of the platelet-related parameters. End-stage renal disease was used as the renal endpoint. A 1:2 propensity score (PS) match was then carried out to eliminate significant differences at baseline. The area under the receiver operating characteristic curve (AUROC), Kaplan-Meier (K-M) curve, and Cox proportional hazards analyses were performed to evaluate their predictive effect.
Results
Without considering the effect of covariates, the K-M curve showed that PLT, PLR, and PAR were strongly correlated with the renal outcomes of IgAN. However, the AUROC revealed that the PAR and PLR had better predictive power than the PLT. Multivariate Cox regression adjusting for demographic data, pathological findings, treatment, and laboratory results indicated that compared with PLR, albumin and PLT, PAR seemed to be a better marker of adverse renal outcome, implying that PAR was the only platelet-related parameter that could be used as an independent risk factor. Notably, high PAR patients seemed to have more severe clinical manifestations and pathological lesions. However, after eliminating the influence of different baselines on outcome variables, the PAR could still predict the poor prognosis of IgAN. To more accurately evaluate the predictive power of the PAR, we analyzed the predictive effect of the PAR on patients with different clinicopathological characteristics through subgroup analysis. It was indicated that the PAR might better predict the prognosis and outcome of patients whose disease was already very severe.
Conclusion
PAR might be used as an independent risk factor for IgAN progression.
Identifiants
pubmed: 35664006
doi: 10.3389/fimmu.2022.842362
pmc: PMC9162245
doi:
Substances chimiques
Albumins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
842362Informations de copyright
Copyright © 2022 Tan, Song, Wang, Dong, Liu, Jiang, Qin, Tang and Qin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Semin Immunopathol. 2021 Oct;43(5):691-705
pubmed: 34674036
Cancer Metastasis Rev. 2017 Jun;36(2):195-198
pubmed: 28667366
Clin J Am Soc Nephrol. 2017 Apr 3;12(4):677-686
pubmed: 28159829
Kidney Int. 2012 Dec;82(12):1304-12
pubmed: 22895518
Clin J Am Soc Nephrol. 2022 Jan;17(1):155-170
pubmed: 34750169
Ther Clin Risk Manag. 2021 Jul 05;17:691-700
pubmed: 34262282
Nat Rev Nephrol. 2012 Dec;8(12):718-24
pubmed: 23090446
Ann Thorac Cardiovasc Surg. 2021 Apr 20;27(2):84-90
pubmed: 33162436
Curr Med Chem. 2019;26(22):4145-4165
pubmed: 28982316
Platelets. 2017 Sep;28(6):576-584
pubmed: 27885913
Am J Clin Nutr. 2011 Sep;94(3):945-54
pubmed: 21813809
Am J Kidney Dis. 2010 Aug;56(2):313-24
pubmed: 20471735
Front Oncol. 2020 Jan 30;10:30
pubmed: 32082998
J Inflamm Res. 2021 Oct 29;14:5647-5652
pubmed: 34744448
Pediatr Nephrol. 2007 Dec;22(12):2011-22
pubmed: 17647026
Mod Rheumatol. 2021 Sep 03;:
pubmed: 34918121
J Hepatol. 2014 Aug;61(2):396-407
pubmed: 24751830
Medicine (Baltimore). 2021 Dec 17;100(50):e28234
pubmed: 34918687
Ren Fail. 2021 Dec;43(1):1359-1367
pubmed: 34592885
Kidney Int. 2012 Oct;82(8):840-56
pubmed: 22895519
Front Med (Lausanne). 2021 Jun 08;8:596151
pubmed: 34169080
Front Immunol. 2021 Aug 12;12:700224
pubmed: 34456912
Cancers (Basel). 2021 Aug 19;13(16):
pubmed: 34439320
J Inflamm Res. 2021 Jul 13;14:3207-3215
pubmed: 34285544
Kidney Int. 2017 May;91(5):1014-1021
pubmed: 28341274
Am J Epidemiol. 2010 Nov 1;172(9):1092-7
pubmed: 20802241
Anticancer Res. 2018 Feb;38(2):987-992
pubmed: 29374731